S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Gold is SOARING – here's what you need to do (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Gold is SOARING – here's what you need to do (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Gold is SOARING – here's what you need to do (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Gold is SOARING – here's what you need to do (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Gold is SOARING – here's what you need to do (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Gold is SOARING – here's what you need to do (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Gold is SOARING – here's what you need to do (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Gold is SOARING – here's what you need to do (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover

Biohaven (BHVN) Stock Forecast & Price Target

$47.31
-0.02 (-0.04%)
(As of 02/23/2024 ET)

Biohaven Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 7 Analyst Ratings

Analysts' Consensus Price Target

$47.50
0.40% Upside
High Forecast$62.00
Average Forecast$47.50
Low Forecast$28.00
TypeCurrent Forecast
2/25/23 to 2/25/24
1 Month Ago
1/26/23 to 1/26/24
3 Months Ago
11/27/22 to 11/27/23
1 Year Ago
2/25/22 to 2/25/23
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$47.50$39.17$29.17$58.32
Predicted Upside0.40% Upside36.89% Upside31.58% Upside16.53% Upside
Get Biohaven Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.


BHVN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BHVN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Biohaven Stock vs. The Competition

TypeBiohavenMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.48
Consensus RatingBuyModerate BuyHold
Predicted Upside0.40% Upside1,899.57% Upside7.54% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/23/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$32.00 ➝ $56.00+15.97%
2/16/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$62.00+26.25%
2/6/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$59.00+25.19%
12/22/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Tsao
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$50.00+31.51%
12/8/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$58.00+75.70%
11/15/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$29.00 ➝ $36.00+18.69%
6/5/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$24.00 ➝ $28.00+29.33%
4/4/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Duncan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight$27.00 ➝ $31.00+123.02%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:09 AM ET.












BHVN Price Target - Frequently Asked Questions

What is Biohaven's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Biohaven stock is Buy based on the current 7 buy ratings for BHVN. The average twelve-month price prediction for Biohaven is $47.50 with a high price target of $62.00 and a low price target of $28.00. Learn more on BHVN's analyst rating history.

Do Wall Street analysts like Biohaven more than its competitors?

Analysts like Biohaven more than other Medical companies. The consensus rating for Biohaven is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how BHVN compares to other companies.

Does Biohaven's stock price have much upside?

According to analysts, Biohaven's stock has a predicted upside of 31.64% based on their 12-month stock forecasts.

What analysts cover Biohaven?

Biohaven has been rated by HC Wainwright, JPMorgan Chase & Co., Robert W. Baird, Royal Bank of Canada, and UBS Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:BHVN) was last updated on 2/25/2024 by MarketBeat.com Staff